Lexicon Pharmaceuticals (LXRX) Q2 FY26 earnings call

Lexicon Pharmaceuticals achieved significant clinical and financial milestones in Q2 FY26, highlighted by the completion of enrollment for its SONATA-HCM study and nearing NDA resubmission for Zynquista in type 1 diabetes. Despite a net loss and lower revenue compared to the prior year due to a one-time licensing payment, the company strengthened its balance sheet with a new debt facility and reiterated its full-year operating expense guidance, positioning itself for potential transformational catalysts in the next 12 months.